Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294346 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
A Phase 2 study of Social Phobia, sponsored by Avera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 15
- Study locations
NCT00294346: Completed Phase 2 study of Social Phobia, sponsored by Avera Pharmaceuticals.
NCT00294346 is a Phase 2 study of Social Phobia that has completed, run by Avera Pharmaceuticals. The registered enrollment target is 180 participants, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (41% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00294346, a Phase 2 study of Social Phobia, has completed, sponsored by Avera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 to placebo (a medically inactive substance) to see if AV608 helps the symptoms of Social Anxiety Disorder. Eligible subjects will be assigned by chance to take either AV608 or placebo for 12 weeks. During the study, subjects will be asked about their overall health and mood and their Social Anxiety Disorder.
Conditions Studied
Interventions
- DRUG AV608
Study Locations (15)
Florida
- CNS Healthcare - Jacksonville
- Comprehensive Neuroscience, Inc. - St. Petersburg
- University of South Florida - Tampa
California
- Southwestern Research, Inc. - Beverly Hills
- Affiliated Research Institute - San Diego
Maryland
- DuPont Clinical Research, Inc. - Rockville
- Capital Clinical Research Associates - Rockville
Texas
- Claghorn-Lesem Research Clinic, LLP - Bellaire
- Croft Group Research Center - San Antonio
Alabama
- Birmingham Research Group, Inc. - Birmingham
Arizona
- Pivotal Research Centers - Mesa
New York
- Medical Research Network, LLC - New York
Ohio
- Hartford Research - Cincinnatti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00294346 record still lists
NCT00294346 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (41% higher).
The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 1 intervention - of which AV608 is the first listed.
NCT00294346 lists 15 locations in 10 states (Florida, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT00294346 about?
NCT00294346 is a clinical study titled "Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder". The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 t...
What is the current status of trial NCT00294346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2006-02. Estimated completion is 2006-12.
What conditions does trial NCT00294346 study?
This clinical trial studies the following conditions: Social Phobia.
What interventions are being tested in trial NCT00294346?
The interventions under investigation include: AV608 (DRUG).
Who is sponsoring clinical trial NCT00294346?
This trial is sponsored by Avera Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00294346 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00294346's enrollment target sits among peer trials
180 4th of 8 higher than 5 of 8 other Social Phobia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Phobia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
COMPLETED · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
COMPLETED · Phase 2
-
Mindful Self-Compassion for Anxiety Disorders and Depression
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia